NEWS
Our Announcements
Publication in Nature Chemistry Demonstrates the Benefits of Native Mass Spectrometry in the Interrogation of Target Ecosystems and Drug Discovery
10 November 2022
Joint publication in Nature Chemistry between OMass Therapeutics’ scientists and co-founder Professor Dame Carol Robinson’s team at Oxford University Data...
Read More
OMass Therapeutics Appoints Dr Jon Roffey as Vice President, Head of Medicinal Chemistry
15 July 2022
Oxford, United Kingdom – 15 July 2022 – OMass Therapeutics (‘OMass’, or ‘the Company’), a biotechnology company that identifies medicines...
Read More
OMass Therapeutics Wins the Oxford Science Park Innovation Award at the Oxfordshire Business Awards
20 June 2022
Oxford, United Kingdom – 20 June 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
Read More
OMass Therapeutics Announces its Attendance at Upcoming Conferences and Events
14 June 2022
Oxford, United Kingdom – 14 June 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
Read More
OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases
28 April 2022
Financing led by new investors, GV, Northpond Ventures and Sanofi Ventures, with existing investors, Syncona, Oxford Science Enterprises, and Oxford...
Read More
OMass CEO Ros Deegan Named as a 2022 In Vivo Rising Leader
19 April 2022
Oxford, United Kingdom – 19 April 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
Read More
Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane Environment
6 April 2022
Oxford, United Kingdom – 6 April 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly...
Read More
OMass Establishes Scientific Advisory Board of Leading Experts in the Use of Biophysical Approaches to Drug Discovery
7 March 2022
Oxford, United Kingdom – 7 March 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
Read More
OMass’ OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D
4 March 2022
Oxford, United Kingdom – 28 February 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
Read More
OMass Therapeutics to Present at Upcoming Conferences
3 March 2022
Oxford, United Kingdom – 21 February 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
Read More
OMass Founder, Professor Dame Carol Robinson, Honoured with the 2022 Louis-Jeantet Prize for Medicine and the 2022 Benjamin Franklin Medal in Chemistry
14 December 2021
Oxford, United Kingdom – 14 December 2021 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
Read More
OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins
4 November 2021
Oxford, United Kingdom – 4 November 2021 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
Read More
OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director
28 July 2020
Oxford, 28 July 2020 – OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical...
Read More
OMass Announces Publication in Nature Methods
15 May 2020
Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in...
Read More
OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences
25 February 2020
Oxford, 25 February 2020 - OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton - OMass Therapeutics...
Read More
OMass Therapeutics Announces £27.5 Million Extended Series A Financing
17 February 2020
Oxford, 17 February 2020 – Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders OMass...
Read More
OMass Therapeutics’ Founder & Scientific Advisor, Professor Carol Robinson, receives a Royal Society Medal
23 July 2019
Oxford, 23 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines,...
Read More
OMass Therapeutics’ Founder & Scientific Advisor Honoured – Professor Carol Robinson wins 2019 Novozymes Prize and Stein & Moore Award –
16 July 2019
Oxford, 16 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines,...
Read More
OMass Therapeutics appoints Jonathan Montagu as Non-Executive Director
12 June 2019
Oxford, 12 June 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines,...
Read More
OMass Therapeutics appoints Rosamond Deegan as Chief Executive Officer
8 May 2019
Oxford, 8 May 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines,...
Read More
DyNAbind and OMass Therapeutics enter collaboration agreement
17 April 2019
Dresden, Germany, 16.04.2019 – DyNAbind GmbH and OMass Therapeutics have entered a collaboration for the discovery of new fragment- and...
Read More
OMass Therapeutics Expands its Senior Leadership Team
27 November 2018
Oxford, 27 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines, today...
Read More
OMass Therapeutics Announces £14 Million Series A Financing to Build a Pipeline of Proprietary Medicines
21 November 2018
Oxford, 20 November 2018 – Developing novel medicines using structural mass spectrometry – OMass Therapeutics (“OMass”), a biopharmaceutical company using...
Read More
OMass Therapeutics is Expanding its Team
20 November 2018
Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines is...
Read More
OMass Technologies Announces Publication Demonstrating the Impact of Lipid interactions on GPCR Signalling in Nature
11 July 2018
Oxford, 11 July 2018 – OMass Technologies (“OMass”), a biotechnology company using structural mass spectrometry to drive drug discovery, today...
Read More
OMass Technologies secures INNOVATE UK funding in collaboration with the University of Oxford
15 June 2018
Oxford, 15 June 2017 – OMass Technologies (“OMass”), a biotechnology company using structural mass spectrometry to drive drug discovery, today...
Read More